TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) in melanoma [1]
_______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
TAFINLAR® in combination with MEKINIST® is indicated in adult patients for the treatment of BRAF V600 positive, unresectable or metastatic melanoma, and in the adjuvant setting for Stage III BRAF V600 positive melanoma, following complete resection.1,2
Please refer to the respective SmPCs for all licensed indications.
Please use the buttons below to find out more about melanoma diagnosis and staging, and TAFINLAR® and MEKINIST® mode of action, efficacy, safety profile and patient management.
References
- Tafinlar (dabrafenib) Summary of Product Characteristics.
- Mekinist (trametinib) Summary of Product Characteristics.